Streetbeat News

Products Services

INCY

Incyte (NASDAQ:INCY) announced that new data from its clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, will be presented at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA). The data includes results from three oral presentations and is expected to contribute to the evidence supporting povorcitinib as a potential treatment for hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Povorcitinib is currently in Phase 2 clinical trials for various conditions, with Phase 3 studies in HS ongoing.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:12 pm

FHTX

Foghorn Therapeutics Inc. (NASDAQ:FHTX) announced that clinical data from the Phase 1 study of FHD-286 in metastatic uveal melanoma will be presented at the ESMO Congress 2023. FHD-286 is a potent, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of BRG1 and BRM, two key regulators within the chromatin regulatory system. In pre-clinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:12 pm

ARDX

Ardelyx, Inc. (NASDAQ:ARDX) announced upcoming data presentations for its drug, tenapanor (XPHOZAH), for hyperphosphatemia at the American Society of Nephrology Kidney Week 2023. The company will present four poster presentations highlighting data from two trials in the U.S. Additionally, Ardelyx's collaboration partner in Japan, Kyowa Kirin Co, Ltd., will present key results from two Phase 3 studies of tenapanor in Japan.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:11 pm

VNRX

VolitionRx Limited (NYSE:VNRX) has published a report summarizing key themes from its recent Key Opinion Leader roundtable on sepsis management. The panel discussed the potential of using Volition's Nu.Q® NETs technology effectively in clinical practice for early diagnosis, treatment guidance, monitoring, and personalized medicine in sepsis patients. The company is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:10 pm

HRMY

Harmony Biosciences reported no statistically significant difference between pitolisant and placebo in its Phase 3 INTUNE study for IH. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:10 pm

ESTA

Establishment Labs Holdings Inc. (NASDAQ:ESTA) announced the two-year clinical results of Mia Femtech and the launch of Zen, its next-generation RFID technology, at the 8th Annual World Symposium on Ergonomic Implants. The Mia Feasibility Clinical Study reported no instances of capsular contracture or rupture in a 100-patient study. The new Zen technology, part of the Zensor RFID platform, is non-ferromagnetic and has the potential to measure temperature and other parameters.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:08 pm

GOOG

GOOGL

Google's Pixel 8 Pro's AI-powered Magic Editor is gaining popularity among users for its ability to edit photos in fun and useful ways. The feature, which processes images on the cloud, can add elements, remove objects, and clean up photos. Despite the early stage of the product, initial reactions suggest a positive reception.

Portfolio Pulse from Rounak Jain

October 13, 2023 | 12:07 pm

COMM

CommScope (NASDAQ:COMM) has announced the launch of its next-generation Extended Spectrum DOCSIS (ESD) STARLINE amplifier and NC4000 optical node platforms supporting DOCSIS 4.0 operation. These solutions offer operators an easy upgrade to their current DOCSIS 3.1 network and a clear path to DOCSIS 4.0 operation in the future, with minimal capital expenditures and service interruption. The platforms will be on display at the SCTE Cable-Tec Expo 2023.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:06 pm

HRMY

Harmony Biosciences has released topline results from the INTUNE Phase 3 study of pitolisant for idiopathic hypersomnia. The study found no statistically significant difference between pitolisant and placebo groups on the Epworth Sleepiness Scale, which was the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:06 pm

CPRX

Catalyst Pharmaceuticals (NASDAQ:CPRX) has announced that the FDA has accepted for review its supplemental New Drug Application (sNDA) to increase the maximum daily dosage of FIRDAPSE from 80mg to 100mg for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). The FDA has assigned a target action date of June 4, 2024. FIRDAPSE is currently approved in the U.S. for the treatment of LEMS in adults and children aged six to seventeen.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:05 pm